Literature DB >> 7829965

Interleukin-2 and human monocyte activation.

I Espinoza-Delgado1, M C Bosco, T Musso, G L Gusella, D L Longo, L Varesio.   

Abstract

The recognition of the monocyte/macrophage-activating properties of IL-2 has broadened our image of the biological effects of this lymphokine from those of a T cell growth factor to those of a molecule with pleiotropic effects. The detailed analysis of the mechanisms of action of IL-2 including its biological effects on different cell types and the regulation of its receptors has increased dramatically the spectrum of the biological responses that can be modified by IL-2. The regulation of the expression of the IL-2 receptor subunits differs in terms of response to extracellular stimuli and intracellular control, suggesting that the response to IL-2 will vary depending on the nature and extent of environmental stimulation. Furthermore, the fact that the IL-2R gamma chain can be part of the receptor for IL-4, IL-7, and perhaps other cytokines indicates that IL-2 may modulate the response of monocytes simply by binding or releasing the IL-2R gamma chain and thus modulating the responsiveness to IL-4 or IL-7. Conversely, the extent of utilization of IL-2R gamma chain by various cytokines may dictate the monocytic response to IL-2. In fact, the availability of IL-2R gamma chain seems to be the limiting factor in the response of monocytes to IL-2. Modulation of cytokine receptors is an integral part of the control of the IL-2 response. The induction of CSF-1 receptor by IL-2 and the positive effect of CSF-1 on the duration of the cytotoxic response in IL-2-stimulated monocytes are an interesting example of a synergistic interaction of potential physiological relevance. The response of monocytes to IL-2 can also be modulated by inhibitory circuits, such as those involving TGF-beta 1, IFN-gamma, and IL-4. However, IFN-gamma and IL-4 can also activate monocytes and the timing and relative concentrations of the various cytokines may be critical variables in determining the ultimate monocyte phenotype. These studies have given us a glimpse of a very complex picture composed of multiple backgrounds and several players. However, the present information is not sufficient to make meaningful predictions of the resulting monocyte phenotype in an inflammatory reaction in which multiple cytokines are involved.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7829965     DOI: 10.1002/jlb.57.1.13

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  12 in total

Review 1.  Antibody-cytokine fusion proteins: applications in cancer therapy.

Authors:  Elizabeth Ortiz-Sánchez; Gustavo Helguera; Tracy R Daniels; Manuel L Penichet
Journal:  Expert Opin Biol Ther       Date:  2008-05       Impact factor: 4.388

2.  CD40-CD40 ligand (CD154) engagement is required but may not be sufficient for human T helper 1 cell induction of interleukin-2- or interleukin-15-driven, contact-dependent, interleukin-1beta production by monocytes.

Authors:  C Ribbens; J M Dayer; C Chizzolini
Journal:  Immunology       Date:  2000-02       Impact factor: 7.397

3.  Interleukin-15 augments superoxide production and microbicidal activity of human monocytes against Candida albicans.

Authors:  N Vázquez; T J Walsh; D Friedman; S J Chanock; C A Lyman
Journal:  Infect Immun       Date:  1998-01       Impact factor: 3.441

4.  Macaques with rapid disease progression and simian immunodeficiency virus encephalitis have a unique cytokine profile in peripheral lymphoid tissues.

Authors:  M S Orandle; K C Williams; A G MacLean; S V Westmoreland; A A Lackner
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

5.  Therapeutic efficacy of Bifidobacterium longum-mediated human interleukin-2 with endostatin or TRAIL in transplanted tumors in mice.

Authors:  Yan Yin; Lei Kou; Jian-Jun Wang; Gen-Xing Xu
Journal:  Exp Ther Med       Date:  2011-12-19       Impact factor: 2.447

6.  Overexpression of interleukin-2 by a recombinant herpes simplex virus type 1 attenuates pathogenicity and enhances antiviral immunity.

Authors:  Homayon Ghiasi; Yanira Osorio; Guey-Chuen Perng; Anthony B Nesburn; Steven L Wechsler
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

7.  Characterisation and expression analysis of interleukin 2 (IL-2) and IL-21 homologues in the Japanese pufferfish, Fugu rubripes, following their discovery by synteny.

Authors:  Steve Bird; Jun Zou; Tomoya Kono; Masahiro Sakai; Johannes Martinus Dijkstra; Chris Secombes
Journal:  Immunogenetics       Date:  2004-12-11       Impact factor: 2.846

8.  Pressure Induced Changes in Adaptive Immune Function in Belugas (Delphinapterus leucas); Implications for Dive Physiology and Health.

Authors:  Laura A Thompson; Tracy A Romano
Journal:  Front Physiol       Date:  2016-09-30       Impact factor: 4.566

Review 9.  Genetically engineered mesenchymal stem cells: targeted delivery of immunomodulatory agents for tumor eradication.

Authors:  Meysam Mosallaei; Miganoosh Simonian; Naeim Ehtesham; Mohammad Reza Karimzadeh; Nasim Vatandoost; Babak Negahdari; Rasoul Salehi
Journal:  Cancer Gene Ther       Date:  2020-05-18       Impact factor: 5.987

10.  Transcriptome sequencing and multi-plex imaging of prostate cancer microenvironment reveals a dominant role for monocytic cells in progression.

Authors:  Niall M Corcoran; Anthony T Papenfuss; Christopher M Hovens; Stefano Mangiola; Patrick McCoy; Martin Modrak; Fernando Souza-Fonseca-Guimaraes; Daniel Blashki; Ryan Stuchbery; Simon P Keam; Michael Kerger; Ken Chow; Chayanica Nasa; Melanie Le Page; Natalie Lister; Simon Monard; Justin Peters; Phil Dundee; Scott G Williams; Anthony J Costello; Paul J Neeson; Bhupinder Pal; Nicholas D Huntington
Journal:  BMC Cancer       Date:  2021-07-22       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.